Eccogene
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing oral small molecules for metabolic and immune disorders.
MetabolicImmunology
Technology Platform
Specialized small molecule drug discovery platform focused on oral therapies for GPCR targets like the GLP-1 receptor.
Opportunities
Enormous global demand for effective, convenient oral therapies for obesity and diabetes.
Risk Factors
Intense competition and high clinical hurdles to demonstrate superiority or differentiation against established injectable products.
Competitive Landscape
Competes directly with global pharma giants in the lucrative but highly competitive GLP-1 and metabolic disease market.